tazobactam has been researched along with Obesity, Morbid in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Caro, L; Huntington, JA; Long, J; Xiao, AJ | 1 |
| Aigner, F; Bonatti, H; Hoeller, E; Kafka, R; Stelzmueller, I; Weiss, H; Wiesmayr, S | 1 |
| Adeyemi, OA; Montevecchi, M; Newman, D; Nicolau, DP; Noskin, GA; Postelnick, MJ; Scheetz, MH | 1 |
3 other study(ies) available for tazobactam and Obesity, Morbid
| Article | Year |
|---|---|
Ceftolozane/tazobactam dose regimens in severely/morbidly obese patients with complicated intra-abdominal infection or complicated urinary tract infection.
Topics: Anti-Bacterial Agents; Cephalosporins; Computer Simulation; Escherichia coli; Escherichia coli Infections; Female; Humans; Intraabdominal Infections; Klebsiella Infections; Klebsiella pneumoniae; Male; Microbial Sensitivity Tests; Middle Aged; Monte Carlo Method; Obesity, Morbid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Urinary Tract Infections | 2018 |
Severe intra-abdominal infection due to Streptococcus Milleri following adjustable gastric banding.
Topics: Abdominal Abscess; Body Mass Index; Combined Modality Therapy; Device Removal; Drainage; Drug Therapy, Combination; Female; Follow-Up Studies; Gastric Balloon; Gastroplasty; Humans; Middle Aged; Obesity, Morbid; Penicillanic Acid; Piperacillin; Postoperative Complications; Severity of Illness Index; Streptococcal Infections; Streptococcus milleri Group; Tazobactam | 2005 |
Serum piperacillin/tazobactam pharmacokinetics in a morbidly obese individual.
Topics: Adult; Drug Therapy, Combination; Humans; Male; Obesity, Morbid; Penicillanic Acid; Piperacillin; Tazobactam | 2007 |